earnings
confidence high
sentiment neutral
materiality 0.65
Q32 Bio Q1 net loss $11.0M; cash $65.5M, runs into 2H'26; first patient dosed in Phase 2a Part B for AA
Q32 Bio Inc.
2025-Q1 EPS reported
-$0.90
- Net loss $(11.0)M ($(0.90)/share) vs. net income $1.0M in Q1 2024; R&D expense $7.1M (down 28% YoY).
- Cash and equivalents $65.5M as of March 31, 2025; expected to fund operations into 2H'26.
- First patient dosed in SIGNAL-AA Phase 2a Part B; topline data expected 1H'26.
- Fast Track designation granted to bempikibart for alopecia areata; durable responses seen in late-breaking AAD presentation.
- First patient dosed in Part A open-label extension; median follow-up 41 weeks shows maintenance or further hair growth.